艾昆纬年IQVIA医药交易半年回顾（英）

White PaperIQVIA Pharma Deals Half-year review of 2024LUCY HAGGERTY, Analyst, Global Market Insights, IQVIA TASKIN AHMED, Associate Director, Global Market Insights, IQVIA AYUSH SAXENA, Senior Insights Associate, Global Market Insights, IQVIASWATI SHARAN, Senior Insights Analyst, Global Market Insights, IQVIA 2 | IQVIA Pharma Deals Half Year Review of 2024Table of contentsIntroduction 1M&A deal volume down yet values soar 2Licensing deal spend rises 5J&J jumps ahead in deal activity rankings 8R&D alliance activity remains muted 10Oncology retains dealmaking lead 12Outlook for H2 2024 13About the authors 14 iqvia.com | 1 iqvia.com | 1The slowdown in deal activity in the life sciences sector that was seen in 2023 continued in H1 2024 as persistent macroeconomic headwinds discouraged dealmakers from signing certain transactions that could be perceived as ‘risky’. M&A activity remained dampened in H1 2024 in terms of deal volume, which was down by 20% from H1 2023. However, the aggregate, mean and median total deal values for these deals increased significantly in H1 2024 (when the Pfizer/Seagen mega-deal announced in H1 2023 was excluded) as big pharma made a return to the dealmaking table. Key players such as Johnson & Johnson (J&J), Merck & Co. and Gilead Sciences signed acquisitions valued at US$3 B or more in H1 2024 to gain access to pipeline-enhancing therapies and technologies.With significant deal activity focused on oncology and immunology assets, J&J achieved the title of the most prolific dealmaker in H1 2024, comfortably ahead of Merck & Co. in second place. In a stark contrast to H1 2023, overall transaction volume for several of the top dealmakers increased in H1 2024. Licensing deal flow for life sciences companies decreased 24% relative to H1 2023, as selective licensees favored quality assets over quantity when bolstering their pipelines. This was further demonstrated by the increase in licensing deal spend and average upfront payments as a greater number of deals focused on assets which were in late stage development. Collaborative R&D activity remained below pre-pandemic levels in H1 2024 as companies continued to narrow their therapeutic focuses on key growth opportunities or products in later stages of development. Oncology was once again the most popular therapy area for dealmaking in terms of deal volume in H1 2024, primarily driven by innovative immuno-oncology treatment approaches for difficult-to-treat cancers. IntroductionKey players such as J&J, Merck & Co. and Gilead Sciences signed acquisitions valued at US$3 B or more in H1 2024 to gain access to pipeline-enhancing therapies and technologies.-20%M&A DEAL VOLUME H1 2024 VS. H1 20232 | IQVIA Pharma Deals Half Year Review of 2024M&A deal volume down yet values soar Overall deal activity remained dampened in the first half of 2024 as remaining uncertainties in the macroeconomic environment deterred cautious dealmakers. Excluding standalone